Key Metrics and Overview

Major Growth Drivers:

What is Driving the Growth of Virtual Biopsy Market?

• Increasing incidence of cancer: As the global burden of cancer increases, clinicians look to non-invasive diagnostics that enable early detection and inform treatment decisions; virtual biopsy has developed to meet those needs.
• Improved imaging technologies and AI-enabled analytics: Advances in high resolution imaging (MRI, CT, ultrasound, OCT) and the use of machine learning algorithms have improved characterisation of tissue without the need for tissue biopsy or sampling.
• Patient-centric, cost-effective healthcare: Virtual biopsy methods reduce procedure-related adverse events and complication rates, speed up turnaround time, and limit the need for repeat invasive biopsies, enhancing health care efficiencies and appealing to patients.
• Expanding telemedicine and remote diagnostic capabilities: As monitoring patients remotely and tele-health become increasingly mainstream
• Shift to personalisation and precision medicine: The health care ecosystem is shifting from one size fits all or generic treatment strategies to more tailored therapies, and virtual biopsy data indicates pathology or tissue characterisation using non-invasive and multi-modal data to inform treatments tailored for patients.
  

  Key Drifts:

  What are the Emerging Trends Virtual Biopsy is Demonstrating?

  • Use of multi-modal imaging platforms: Majority of virtual biopsy uses these platforms made up of MRI
  • Expanding into therapeutic areas beyond oncology: Cancer continues to be a key focus of research in virtual biopsy but, it has now expanded into cardiovascular, neurological, and gastroenterological studies, growing the market.
  • Cloud-based and remote-to-point of care solutions: Mobile imaging devices, cloud-based analytics, and remote reporting, are bringing virtual biopsy solutions beyond tertiary hospitals to out-patient clinic locations and non-healthcare provider locations.
  • Regulatory and reimbursement good faith: As virtual biopsy technologies developing and maturing, the regulators and payers are moving towards frameworks for AI-based diagnostics
    Become a valued research partner with us -

    Significant Challenge:

    Despite the promise, albeit it faces challenges to overcome. These include limited large-scale clinical outcome data and variability in imaging protocols and algorithm performance as well as limited standardisation across centres, which ultimately leads to clinician scepticism in adopting new technologies. Similarly, the cost of advanced imaging equipment, AI software integration, and upgrading infrastructure is a barrier, especially for smaller or resource-poor facilities. If robust reimbursements pathways and evidence of cost-effectiveness do not exist, it may be anticipated that the uptake of new technology will take longer than previously anticipated, irrespective of speed or availability of technology capabilities.

    Regional Analysis:

    North America is the leader in the virtual biopsy market and is projected to have the largest share during the forecast period. Their first-place position is based on several factors including a highly advanced healthcare system, rapid adoption of advanced imaging and artificial intelligence technology, a favourable reimbursement landscape, and substantial public and private investment in research and development.

    The United States in particular benefits from a large oncology population digital health

    The Asia-Pacific region is expected to be the fastest growth geographical segment in the virtual biopsy market. Their growth is underpinned by increasing healthcare spending, increasing cancer rates, expanding access to diagnostic imaging infrastructure, and government incentives towards early detection and preventative care. The expanding middle-class settlers in countries like China and India, alongside rapid establishment of a private health and diagnostic infrastructure will provide further incentive to adopt non-invasive imaging tools in the oncology space. Additionally, lower baseline adoption and untapped potential support accelerated growth in this region compared to more mature markets.

    Get the latest insights on life science industry segmentation with our Annual Membership:

    Segmental Insights:

    By Therapeutic Area:

    The oncological disorders section had the most significant share in the virtual biopsy market in 2024. As a result of ongoing demand for effective cancer diagnostics

    By Type of Cancer:

    In 2024, among the various cancer types, the breast-cancer segment had the largest share of the market due to high volumes of screening, ongoing public awareness campaigns, and the implementation of minimally invasive diagnostic workflows in breast imaging. Virtual biopsy methods in breast oncology provide a more patient-friendly option than traditional biopsy methods.

    The fastest growing segment in the market during the timeframe studied will be prostate cancer segment in terms of specific cancer types. The prostate cancer segment is poised to grow fastest, fuelled by the aging global male population, increased screening rates, and rising preferences for non-invasive diagnostics that reduce complications associated with biopsy. Virtual biopsy solutions for prostate imaging and AI-based lesion characterization are gaining traction in this segment.

    By Type of Imaging Technology:

    In 2024, CT-based imaging accounted for the largest share of the virtual biopsy technologies market. This is due to their widespread accessibility, high volume of imaging in clinical settings, and established infrastructure of departments providing diagnostic imaging services. CT enables high-resolution morphological imaging which becomes the basis for virtual biopsy workflows.

    Magnetic resonance imaging is expected to witness the fastest growth in the upcoming years. The magnetic resonance imaging segment is expected to grow fastest, stemming from advances in AI-augmented MRI

    By End Users:

    The hospital and clinics segment accounted for the largest market share in 2024. The hospital & clinics end-user segment accounted for the largest market share in 2024, as these facilities have all the necessary imaging infrastructure, specialist personnel and incorporated diagnostic workflows required to deploy virtual biopsy technology. It is the large hospitals that drive more rapid adoption of advanced imaging and AI-enabled diagnostics.

    The diagnostic centers segment is expected to grow at the fastest rate in the forecast period. Diagnostic centres are expected to be the fastest growing segment in the years to come, as they continue to upgrade imaging equipment, incorporate AI-based analysis to manage imaging results, and extend their services into outpatient and community settings. diagnostic centres also provide growth potential for the adoption of virtual biopsy outside of traditional large hospital systems.

    Browse More Insights of Towards Healthcare:

    The global cancer biopsy market

    The global pleural biopsy market

    The tumor fluid biopsy market

    The global liquid biopsy market

    Within this space, the breast cancer liquid biopsy market

    The global liquid biopsy IVD market

    Complementing this trend, the liquid biopsy tube market

    Recent Developments:

    • In February 2025, Hologic, Inc. obtained CE-mark approval for its Airm Contrast Biopsy Software, which combines contrast-enhanced mammography with accurate lesion targeting to streamline biopsy procedures, marking progression toward non-invasive diagnostics in breast care.
      

    Virtual Biopsy Market Key Players List:

    • Hologic, Inc
    • Danaher Corporation
    • Becton, Dickinson, and Company
    • Medtronic plc
    • Olympus Corporation
    • CONMED Corporation
    • GE Healthcare
    • Koninklijke Pjilips N.V.
    • FUJIPFILMS Corporation
    • Siemens Healthineers
    • Hitachi, Ltd
      

    Segments Covered in the Report

    By Target therapeutic area

    • Oncological disorders
    • Neurological disorders
    • Cardiovascular disorders
    • Ophthalmological disorders
    • Endocrine disorders
    • Gastrointestinal disorders
    • Others
      

    By Type of cancer targeted

    • Solid malignancies
    • Breast cancer
    • Lung cancer
    • Prostate cancer
    • Colorectal cancer
    • Brain cancer
    • Others
      

    By Type of imaging technologies

    • Magnetic resonance imaging
    • Computed tomography
    • X-ray
    • Others

    By End users

    • Hospitals and clinics
    • Research institutes
    • Diagnostic centers
    • Others

    By Region

    • North America
      • U.S.
      • Canada
    • Europe
      • UK
      • Germany
      • France
      • Italy
      • Spain
      • Denmark
      • Sweden
      • Norway
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Australia
      • Thailand
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
      • Kuwait
    Immediate Delivery Available | Buy This Premium Research @

    Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

    Access the Dashboard:

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research
    You can place an order or ask any questions, please feel free to contact us at ...

    Europe Region: +44 778 256 0738

    North America Region: +1 8044 4193 44

    APAC Region: +91 9356 9282 04

    Web:

    Our Trusted Data Partners

    Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics
    Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest